Epitnezumab Meets Primary, Secondary Endpoints in PROMISE 2
The Alder Pharmaceuticals product showed an average reduction of 8.2 monthly headache days.
Read More
Andrew Alexis, MD, MPH: The State of Atopic Dermatitis
Andrew Alexis, MD, MPH, discussed the current state of care for atopic dermatitis and spoke about how 2017 offered much to look forward to for the field of dermatology.
Aging Population Raises Concerns About Pain Management Strategies
With the total population over age 65 expected to more than double by 2050, pain management strategies for the elderly must be re-examined.
Anne M. Ditto, MD: Therapies for Different Asthma Phenotypes
Anne M. Ditto, MD, discussed the state of therapies for differing asthmatic phenotypes, as well as what is in the pipeline that could be used to treat these patients in the future.
CSF Biomarker Linked to Phenotype of Patients With PD
The findings could have implications for clinical trial subject selection and testing of symptomatic and disease-modifying therapies in PD.
FDA Rejects AG200-15 (Agile Therapeutics) Hormonal Contraceptive Patch
The patch was originally submitted for FDA approval in 2012, but Agile received a Complete Response Letter which identified concerns about the therapy’s efficacy.
Diabetes, Not Metformin, Increases Risk of Poor Pregnancy Outcomes
The risk of major birth defects was 6% higher due to a diagnosis of pre-gestational diabetes than without the presence of the condition.
NYU Fresco Institute Takes a Practical Approach to Parkinson Disease
"By the middle of next year or this time next year, it will be clear to people even outside the movement disorder community that this is a powerhouse center." —Steven J. Frucht, MD
Patients With T2D Taking Metformin Have Lowest Adherence
Research showed that 30% of metformin doses were not taken by patients with type 2 diabetes.
Doximity Data Show Job Boom in Boston, Growth in Geriatrics
Doximity's US Physician Employment Report 2017 showed the implications of the physician job market in metropolitan areas across the US.
FDA Grants Breakthrough Designation to Fingolimod (Gilenya, Novartis)
The oral DMT showed an 82% reduction in relapses compared to interferon ß-1a.
Cariprazine (VRAYLAR, Allergan) Meets Primary Endpoint in Phase 3 Trial
The antipsychotic drug met the primary endpoints for efficacy and safety in both 1.5 mg and 3 mg doses for patients with acute bipolar I disorder.
Traumatic Brain Injury Linked to Gastrointestinal Changes
This marks the first time that an observed permeability change has occurred in the gut due to brain injury.
Kevin Maki, PhD: The Impact of the New AHA/ACC Hypertension Guidelines
Kevin Maki, PhD, discussed the impact that the new guidelines for hypertension from the AHA and the ACC will have on patients and physicians.
20% of Elderly Patients Report Health Care Discrimination
The analysis found that an estimated 27% of Black Americans, 17% of White Americans, and 16% of Hispanic Americans experienced health care discrimination.
FDA Fast Tracks Renova Therapeutics' RT-100 AC6 Gene Transfer Therapy
Renova Therapeutics is planning a 536-patient phase 3 trial, FLOURISH, to begin in early 2018.
Prescription Opioid Users Raise Risk of Use for Others in Household
Compared to households with only NSAIDs, those who live with prescription opioid users are 0.71% more likely to use unprescribed opioids.
FDA Streamlines Approach for Bacterial, Fungal Breakpoint Information
The FDA announced a webpage that will provide consistently updated information on the breakpoints for bacterial and fungal infections.
FDA Committee Advises Against Instrinsic Therapeutics Barricad Spinal Device
The Intristic Therapeutics product was advised against by the FDA's Advisory Committee by a vote of 5-8, with 1 abstention.
Kevin Maki, PhD: The State of the Lipid Space and the Need for More In-Between Therapies
Kevin Maki, PhD, discussed the current state of lipid care in the United States.
Andrew R. Waxler, MD, FACC: Benefits of the Corus CAD Test
Andrew R. Waxler, MD, FACC, discussed the Corus CAD test, which allows cardiologists to rule out multiple conditions during diagnosis for cardiovascular conditions.
Alzheimer Prevalence Expected to More Than Double by 2060
A UC-Irvine developed model predicts that by 2060, more than 15 million Americans will be living with cognitive impairment due to AD.
Kevin Maki, PhD: Balancing Cost and Benefit With PCSK9 Inhibitors
Kevin Maki, PhD, discussed weighing the benefits of PCSK9 inhibitors against their high price tag.
FDA Gives Final Approval to Sanofi's Insulin Lispro Injection (Admelog)
Admelog was tentatively approved on Sept. 1, 2017, based on phase 3 clinical trial data for Humalog.
SIGA Technologies Submits NDA for Smallpox Therapy Tecovirimat (TPOXX)
Amidst fears of the virus being used as a biological weapon, tecovirimat seeks to be the first approved smallpox therapy.
Closed-Loop Insulin Pump Brightens Future of Diabetes Management
Medtronic's MiniMed 670G Insulin Pump System alleviates a huge patient burden for T1D patients and gives hope for a similar device for T2D.
GluCEST Shows Improved Signal in MRI-Negative Patients
Single-slice GluCEST has been shown to lateralize and localize epileptogenic regions of the hippocampus on 7 Tesla MRI in MRI-negative patients.
Maternal Mortality 8 Times Higher With Epilepsy Than Without
Maternal mortality for women with epilepsy is considerably higher than for women without the condition, according to new data.
Real-World Data on Perampanel Shows High Mediciation Adherence
More than half of patients on the epilepsy therapy remained on the treatment after 24 months.
Ganaxolone Shown to Reduce Seizure Frequency
An open-label study of ganaxolone has shown that the therapy is capable of reducing the frequency of seizures and increasing the number of seizure-free days in young patients.